Quick Answer
Neuphoria Therapeutics Inc. reported Total Assets of $28.59 million for fiscal year 2025.
Neuphoria Therapeutics Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $28.59M | +3.4% |
| 2024 | $27.65M | -3.2% |
| 2023 | $28.56M | -56.3% |
| 2022 | $65.31M | +20.4% |
| 2021 | $54.26M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $36.60M | +101.4% | +33.8% |
| September 30, 2025 | $27.34M | +19.3% | -4.4% |
| June 30, 2025 | $28.59M | +3.4% | -6.9% |
| March 31, 2025 | $30.71M | — | +69.0% |
| December 31, 2024 | $18.17M | — | -20.7% |
| September 30, 2024 | $22.92M | — | -17.1% |
| June 30, 2024 | $27.65M | — | — |
- Neuphoria Therapeutics Inc. showed an increase of +3.4% in Total Assets compared to the prior fiscal year.
- Over the 2021–2025 period, Neuphoria Therapeutics Inc.’s total assets has declined by 47.3% (from $54.26 million to $28.59 million).
- The most recent figure is from Neuphoria Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 29, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: